Cargando…
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
INTRODUCTION: Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of...
Autores principales: | Zarębska-Michaluk, Dorota, Piekarska, Anna, Jaroszewicz, Jerzy, Klapaczyński, Jakub, Sitko, Marek, Tudrujek-Zdunek, Magdalena, Tomasiewicz, Krzysztof, Belica-Wdowik, Teresa, Pabjan, Paweł, Lorenc, Beata, Czauż-Andrzejuk, Agnieszka, Tronina, Olga, Krygier, Rafał, Dobracki, Witold, Buczyńska, Iwona, Simon, Krzysztof A., Dybowska, Dorota, Halota, Waldemar, Pawłowska, Małgorzata, Citko, Jolanta, Laurans, Łukasz, Mazur, Włodzimierz, Janczewska, Ewa, Socha, Łukasz, Deroń, Zbigniew, Berak, Hanna, Flisiak, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710286/ https://www.ncbi.nlm.nih.gov/pubmed/36457986 http://dx.doi.org/10.5114/aoms.2019.86569 |
Ejemplares similares
-
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018) -
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021) -
HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)